Literature DB >> 7057383

Contribution of lungs to total body clearance: linear and nonlinear effects.

J M Collins, R L Dedrick.   

Abstract

The contribution of the lungs to the total body clearance of drugs is examined in a framework that emphasizes their anatomical position. For intravenous administration, the lung is the only organ other than blood that can account for a total body clearance in excess of the cardiac output. Systemic arterial drug concentration and tissue drug exposure are inversely proportional to total body clearance. Although the role of the lung has been overshadowed by that of the liver, several examples are presented to demonstrate that relatively small amount of pulmonary activity can produce a large reduction in systemic arterial drug concentration. For oral administration, first-pass elimination by the liver and lungs in series results in a synergistic increase in total body clearance. Nonlinear effects caused by saturation of elimination pathways are also examined. Increased emphasis on experimental investigation of the pulmonary contribution is warranted, especially for drugs with high apparent clearance.

Mesh:

Substances:

Year:  1982        PMID: 7057383     DOI: 10.1002/jps.2600710117

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration and measurement.

Authors:  R Mehvar
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Definition of pharmacokinetic parameters: influence of the sampling site.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

Review 4.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

6.  Comparison of benzo(a)pyrene metabolism in isolated perfused rat lung and liver.

Authors:  M Mollière; H Foth; R Kahl; G F Kahl
Journal:  Arch Toxicol       Date:  1987-06       Impact factor: 5.153

7.  Potential pulmonary uptake and clearance of morphine in postoperative patients.

Authors:  M P Persson; L Wiklund; P Hartvig; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species.

Authors:  J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC.

Authors:  Yasuteru Kondo; Tatsuki Morosawa; Soichiro Minami; Yasuhito Tanaka
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.